TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06312384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation
Description: a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation
Description: The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
Study: NCT05660252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative request
Description: The relative is approached by the clinical team and an organ procurement coordinator together.
Study: NCT05122624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PredicTB score
Description: This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score.
Study: NCT05381454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone/mitoquinol mesylate
Description: Mitoquinone/mitoquinol mesylate
Study: NCT05909553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study: NCT05911126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
Description: Tablet form received prior to the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
Description: Tablet form received prior to the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet
Description: Tablet form received prior to the procedure
Study: NCT04878068

Intervention type: DEVICE
Intervention: Theram COVID-19 Rapid Antigen Test
Description: The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
Study: NCT06067867

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT05564000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dating Violence Prevention Program
Description: We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
Study: NCT05057871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse electromagnetic field therapy
Description: It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham pulse electromagnetic field therapy
Description: Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
Study: NCT05677425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement
Description: Temperature measurement in the renal pelvis during ureteroscopic laser activation.
Study: NCT06407219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Gait Training
Description: The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Gait Training
Description: The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
Study: NCT05177640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Duramycin
Description: This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
Study: NCT04819789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ dry powder porridge
Description: At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ wet porridge
Description: At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermotein™ modified wet porridge
Description: At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mycoprotein porridge (matching control)
Description: At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
Study: NCT04899115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral vancomycin
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vancomycin
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Study: NCT05909020

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT06491355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mfolfox6 and hlx04 regimen and Serplulimab
Description: mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mfolfox6 and hlx04 regimen
Description: In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Study: NCT05563545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK-CD19 Cells
Description: CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.
Study: NCT05104073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Provided with educational materials, guidelines and instructions.
Study: NCT05763914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the incidence of hand eczema
Description: Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the incidence of hand eczema
Description: Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in the incidence of hand eczema
Description: Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in severity of hand eczema
Description: Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in severity of hand eczema
Description: Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in severity of hand eczema
Description: Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the number of self-reported days with absence from work due to having hand eczema
Description: Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the number of self-reported days with absence from work due to having hand eczema
Description: Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in the number of self-reported days with absence from work due to having hand eczema
Description: Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the number of participants being forced to change their job due to having hand eczema
Description: Self-reported change of job due to having hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the number of participants being forced to change their job due to having hand eczema
Description: Self-reported change of job due to having hand eczema. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in the number of participants being forced to change their job due to having hand eczema
Description: Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
Study: NCT05511064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood circulation device
Description: Blood circulation device of CGM MB-1701
Study: NCT06224790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Capsule Pirfenidone 1200mg/ day in divided doses for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Capsules 3 times a day for 3 months
Study: NCT05763914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in The Quality Of Life in in relation to hand eczema
Description: Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in The Quality Of Life in in relation to hand eczema
Description: Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in The Quality Of Life in in relation to hand eczema
Description: Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the level of knowledge regarding skin care and protection.
Description: Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in the level of knowledge regarding skin care and protection.
Description: Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Change in the level of knowledge regarding skin care and protection.
Description: Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
Study: NCT04565548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program for hypertensive patients
Description: The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
Study: NCT05857722

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Jóvenes Capibara
Description: Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jóvenes Capibara
Description: Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
Study: NCT05621447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-303, [14C]TAS-303
Description: oral administration on day 1
Study: NCT04880668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerosol Box (Splashguard)
Description: The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
Study: NCT05824000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye drops for itchy and water eyes
Description: Ocular drops for itchy and watery eyes
Study: NCT04792476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
Study: NCT06541496

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.
Study: NCT05073419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Routine monitoring of post AMI patient with clinic visits

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICM Implantation
Description: Implantation of ICM through small incision (2 mm) under the skin
Study: NCT06541496

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous MSOT imaging of muscle regions.
Study: NCT05078203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 36 minutes of Exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 36 minutes of Exercise
Study: NCT04126044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06439535 (CN)
Description: This is the test drug Pfizer biosimilar of bevacizumab-EU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab - EU
Description: This is the reference drug bevacizumab sourced from EU
Study: NCT05636813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
Study: NCT06278805

Intervention type: OTHER
Intervention: The reliability and validity study of the T-LUNS
Description: To test the reliability and validity of the T-LUNS, 110 chronic stroke survivors fulfilling the inclusion / exclusion criteria at the 3 study sites will be assessed. The assessment of each patient will include recording of the demographic and clinical characteristics and administration of the T-LUNS as well as the Turkish version of the Stroke Impact Scale 3.0 (SIS). For the assessment of test-retest reliability of the T-LUNS, half of the participants (n= 55) will fill in the T-LUNS again, 2 weeks after the first administration.
Study: NCT03164447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: Monoclonal antibody by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background therapy (OBT)
Description: The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
Study: NCT04654377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised education
Description: Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
Study: NCT06376487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow rate evaluation
Description: Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
Study: NCT04904471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
Study: NCT04907292

Intervention type: OTHER
Intervention: Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool
Description: The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.

Intervention type: OTHER
Intervention: Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool
Description: The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.